Health1 min read

STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more

By · Via STAT Health · Published by Everything Blog

In short

The FDA has effectively halted the Commissioner’s National Priority Voucher program, which aimed to shorten drug reviews to under two months for select treatments. The initiative sparked backlash over worries that companies lowering drug prices per presidential requests would receive preferential regulatory treatment. Meanwhile, the Senate health committee scheduled a November 18 vote on Heidi Overton's nomination to head the agency. Overton's confirmation remains in jeopardy because Committee Chair Bill Cassidy has not decided whether to support her.

Key points

  • The FDA halted an accelerated review program amid ethical concerns regarding political in…: The FDA halted an accelerated review program amid ethical concerns regarding political influence and price concessions.
  • Senate Republicans face a tight deadline to confirm regulatory leadership before Democrat…: Senate Republicans face a tight deadline to confirm regulatory leadership before Democrats assume power in January.
  • A single Republican defection on the panel could derail Heidi Overton's confirmation if D…: A single Republican defection on the panel could derail Heidi Overton's confirmation if Democrats unite against her.

Sources checked by our analysis pipeline: 1

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing a fresh cuppa stimulation and invite you to join us. Remember, a prescription is not required. Our choice today is ginger peach. Meanwhile, here are a few items of interest. Hope you have a smashing day and, of course, do stay in touch. …

The U.S. Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary, Reuters reports. Launched in June 2025, the Commissioner’s National Priority Voucher program aimed to slash drug review timelines to just one to two months for therapies addressing national priorities, such as urgent unmet health needs. But critics pointed to possible preferential treatment for companies meeting demands of President Trump, such as offering drugs at lower prices. No new…

Health